
|Videos|July 31, 2020
ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVO
Author(s)Alex Delaney-Gesing
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Advertisement
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Duravyu misses LUGANO endpoint but cuts treatment burden by 42%
4
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
5



















